Browse Arkansas Code titles and sections
21 U.S.C. § 360fff–3 — GRASE determination
Federal law — U.S. Code and appendices · legal_authorities
**(a) Review of new request**
(1) **Proposed sunscreen order** — In the case of a request under [section 360fff–1 of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section360fff-1&num=0&edition=prelim), not later than 300 calendar days after the date on which such request is filed under subsection (b)(2)(A) or (b)(3)(B)(ii)(III) of [section 360fff–2 of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section360fff-2&num=0&edition=prelim), the Secretary—
(A) may convene a meeting of the Advisory Committee to review such request; and
(B) shall complete the review of such request and issue a proposed sunscreen order with respect to such request.
(2) **Proposed sunscreen order by Commissioner** — If the Secretary does not issue a proposed sunscreen order under paragraph (1)(B) within such 300-day period, the sponsor of such request may notify the Office of the Commissioner of such request and request review by the Office of the Commissioner. If such sponsor so notifies the Office of the Commissioner, the Commissioner shall, not later than 60 calendar days after the date of notification under this paragraph, issue a proposed sunscreen order with respect to such request.
(3) **Public comment period** — A proposed sunscreen order issued under paragraph (1)(B) or (2) with respect to a request shall provide for a period of 45 calendar days for public comment.
(4) **Meeting** — A sponsor may request, in writing, a meeting with respect to a proposed sunscreen order issued under this subsection and described in subparagraph (B) or (C) of [section 360fff(7) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section360fff/7&num=0&edition=prelim), not later than 30 calendar day
Source: Supplied U.S. Code snapshot — release unconfirmed · 21 U.S.C. § 360fff–3
Stored review status: release_metadata_unconfirmed. A text match is a research starting point; applicability is not established.
Original supplied file — preserved unchanged
Download original Markdown file
File SHA-256: cd3d68d88bb63af96bf7bdba15ff05120ba206ca68f3b28dff76960914082805. The original may include catalog metadata, neighboring provisions, or embedded records outside this collection's scope. Search shows only the selected federal record. Historical editions and unverified snapshots are not a statement of current law.
Authority boundary: historical or unconfirmed source not current law verified.
Record provenance
Stable record: federal_law:legal_authorities:record_usc_5a6c5ced8428bab431079e60
Source file: Laws/federal/codes/united-states-code/title-21/section-360fff3-grase-determination--5e06375ea0.md
Pages: Not recorded – Not recorded
Passage SHA-256: 3b2d005c0c0a2992abcb1a4177b2ebf9dd3f3bb1dafddaa237628d6967d74e59
Source location: Title 21, Chapter 9, § 360fff–3; chapter-009-federal-food-drug-and-cosmetic-act.md
Stored source content
**(a) Review of new request**
(1) **Proposed sunscreen order** — In the case of a request under [section 360fff–1 of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section360fff-1&num=0&edition=prelim), not later than 300 calendar days after the date on which such request is filed under subsection (b)(2)(A) or (b)(3)(B)(ii)(III) of [section 360fff–2 of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section360fff-2&num=0&edition=prelim), the Secretary—
(A) may convene a meeting of the Advisory Committee to review such request; and
(B) shall complete the review of such request and issue a proposed sunscreen order with respect to such request.
(2) **Proposed sunscreen order by Commissioner** — If the Secretary does not issue a proposed sunscreen order under paragraph (1)(B) within such 300-day period, the sponsor of such request may notify the Office of the Commissioner of such request and request review by the Office of the Commissioner. If such sponsor so notifies the Office of the Commissioner, the Commissioner shall, not later than 60 calendar days after the date of notification under this paragraph, issue a proposed sunscreen order with respect to such request.
(3) **Public comment period** — A proposed sunscreen order issued under paragraph (1)(B) or (2) with respect to a request shall provide for a period of 45 calendar days for public comment.
(4) **Meeting** — A sponsor may request, in writing, a meeting with respect to a proposed sunscreen order issued under this subsection and described in subparagraph (B) or (C) of [section 360fff(7) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section360fff/7&num=0&edition=prelim), not later than 30 calendar days after the Secretary issues such order. The Secretary shall convene a meeting with such sponsor not later than 45 calendar days after such request for a meeting.
(5) **Final sunscreen order** — With respect to a proposed sunscreen order under paragraph (1)(B) or (2)—
(A) the Secretary shall issue a final sunscreen order—
(i) in the case of a proposed sunscreen order described in subparagraph (A) or (B) of [section 360fff(7) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section360fff/7&num=0&edition=prelim), not later than 90 calendar days after the end of the public comment period under paragraph (3); or
(ii) in the case of a proposed sunscreen order described in subparagraph (C) of [section 360fff(7) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section360fff/7&num=0&edition=prelim), not later than 210 calendar days after the date on which the sponsor submits the additional information requested pursuant to such proposed sunscreen order; or
(B) if the Secretary does not issue such final sunscreen order within such 90- or 210-calendar-day period, as applicable, the sponsor of such request may notify the Office of the Commissioner of such request and request review by the Office of the Commissioner.
(6) **Final sunscreen order by Commissioner** — The Commissioner shall issue a final sunscreen order with respect to a proposed sunscreen order subject to paragraph (5)(B) not later than 60 calendar days after the date of notification under such paragraph.
**(b) Review of pending requests**
(1) **In general** — The review of a pending request shall be carried out by the Secretary in accordance with this subsection.
(2) **Inapplicability of sections 360fff–1 and 360fff–2 of this title** — Sections 360fff–1 and 360fff–2 of this title shall not apply with respect to any pending request.
(3) **Feedback letters as proposed sunscreen order** — Notwithstanding the requirements of [section 360fff(7) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section360fff/7&num=0&edition=prelim), a letter issued pursuant to section 330.14(g) of title 21, Code of Federal Regulations before November 26, 2014, with respect to a pending request, shall be deemed to be a proposed sunscreen order and displayed on the Internet website of the Food and Drug Administration. Notification of the availability of such letter shall be published in the Federal Register not later than 45 calendar days after November 26, 2014.
(4) **Proposed sunscreen order** — In the case of a pending request for which the Secretary has not issued a letter pursuant to section 330.14(g) of title 21, Code of Federal Regulations before November 26, 2014, the Secretary shall complete review of such request and, not later than 90 calendar days after November 26, 2014, issue a proposed sunscreen order with respect to such request.
(5) **Proposed sunscreen order by Commissioner** — If the Secretary does not issue a proposed sunscreen order under paragraph (4), or the Secretary does not publish a notification of the availability of a letter under paragraph (3), as applicable, the sponsor of such request may notify the Office of the Commissioner of such request and request review by the Office of the Commissioner. The Commissioner shall, not later than 60 calendar days after the date of notification under this paragraph, issue a proposed order with respect to such request.
(6) **Public comment period** — A proposed sunscreen order issued under paragraph (4) or (5), or a notification of the availability of a letter under paragraph (3), with respect to a pending request shall provide for a period of 45 calendar days for public comment.
(7) **Meeting**
(A) *In general* — A sponsor may request, in writing, a meeting with respect to a proposed sunscreen order issued under this subsection, including a letter deemed to be a proposed sunscreen order under paragraph (3), not later than 30 calendar days after the Secretary issues such order or the date upon which such feedback letter is deemed to be a proposed sunscreen order, as applicable. The Secretary shall convene a meeting with such sponsor not later than 45 calendar days after the date of such request for a meeting.
(B) *Confidential meetings* — A sponsor may request one or more confidential meetings with respect to a proposed sunscreen order, including a letter deemed to be a proposed sunscreen order under paragraph (3), to discuss matters relating to data requirements to support a general recognition of safety and effectiveness involving confidential information and public information related to such proposed sunscreen order, as appropriate. The Secretary shall convene a confidential meeting with such sponsor in a reasonable time period. If a sponsor requests more than one confidential meeting for the same proposed sunscreen order, the Secretary may refuse to grant an additional confidential meeting request if the Secretary determines that such additional confidential meeting is not reasonably necessary for the sponsor to advance its proposed sunscreen order, or if the request for a confidential meeting fails to include sufficient information upon which to base a substantive discussion. The Secretary shall publish a post-meeting summary of each confidential meeting under this subparagraph that does not disclose confidential commercial information or trade secrets. This subparagraph does not authorize the disclosure of confidential commercial information or trade secrets subject to 552(b)(4) 11 So in original. Probably should be preceded by “section”. of title 5 or [section 1905 of title 18](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title18-section1905&num=0&edition=prelim).
(8) **Advisory Committee** — In the case of a proposed sunscreen order under paragraph (3), (4), or (5), an Advisory Committee meeting may be convened for the purpose of reviewing and providing recommendations regarding the pending request.
(9) **Final sunscreen order** — In the case of a proposed sunscreen order under paragraph (3), (4), or (5)—
(A) the Secretary shall issue a final sunscreen order with respect to the request—
(i) in the case of a proposed sunscreen order described in subparagraph (A) or (B) of [section 360fff(7) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section360fff/7&num=0&edition=prelim), not later than 90 calendar days after the end of the public comment period under paragraph (6); or
(ii) in the case of a proposed sunscreen order described in subparagraph (C) of [section 360fff(7) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section360fff/7&num=0&edition=prelim)—
(I) if the Advisory Committee is not convened under paragraph (8), not later than 210 calendar days after the date on which the sponsor submits the additional information requested pursuant to such proposed sunscreen order, which shall include a rationale for not convening such Advisory Committee; or
(II) if the Advisory Committee is convened under paragraph (8), not later than 270 calendar days after the date on which the sponsor submits such additional information; or
(B) if the Secretary does not issue such final sunscreen order within such 90-, 210-, or 270-calendar-day period, as applicable, the sponsor of such request may notify the Office of the Commissioner about such request and request review by the Office of the Commissioner.
(10) **Final sunscreen order by Commissioner** — The Commissioner shall issue a final sunscreen order with respect to a proposed sunscreen order subject to paragraph (9)(B) not later than 60 calendar days after the date of notification under such paragraph.
**(c) Advisory Committee** The Secretary shall not be required to—
(1) convene the Advisory Committee—
(A) more than once with respect to any request under [section 360fff–1 of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section360fff-1&num=0&edition=prelim) or any pending request; or
(B) more than twice in any calendar year with respect to the review under this section; or
(2) submit more than a total of 3 requests under [section 360fff–1 of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section360fff-1&num=0&edition=prelim) or pending requests to the Advisory Committee per meeting.
**(d) No delegation** Any responsibility vested in the Commissioner by subsection (a)(2), (a)(6), (b)(5), or (b)(10) shall not be delegated.
**(e) Effect of final sunscreen order**
(1) **In general**
(A) *Sunscreen active ingredients determined to be GRASE* — Upon issuance of a final sunscreen order determining that a nonprescription sunscreen active ingredient or combination of nonprescription sunscreen active ingredients is GRASE and is not misbranded, a sunscreen containing such ingredient or combination of ingredients shall be permitted to be introduced or delivered into interstate commerce for use under the conditions described in such final sunscreen order, in accordance with all requirements applicable to drugs not subject to [section 353(b)(1) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section353/b/1&num=0&edition=prelim), for so long as such final sunscreen order remains in effect.
(B) *Sunscreen active ingredients determined not to be GRASE* — Upon issuance of a final sunscreen order determining that a nonprescription sunscreen active ingredient or combination of nonprescription sunscreen active ingredients is not GRASE and is misbranded, a sunscreen containing such ingredient or combination of ingredients shall not be introduced or delivered into interstate commerce, for use under the conditions described in such final sunscreen order, unless an application is approved pursuant to [section 355 of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section355&num=0&edition=prelim) with respect to a sunscreen containing such ingredient or combination of ingredients, or unless conditions are later established under which such ingredient or combination of ingredients is later determined to be GRASE and not misbranded under the over-the-counter drug monograph system.
(2) **Amendments to final sunscreen orders**
(A) *Amendments at initiative of Secretary* — In the event that information relevant to a nonprescription sunscreen active ingredient or combination of nonprescription sunscreen active ingredients becomes available to the Secretary after issuance of a final sunscreen order, the Secretary may amend such final sunscreen order by issuing a new proposed sunscreen order under subsection (a)(1) and following the procedures set forth in this section.
(B) *Petition to amend final order* — Any interested person may petition the Secretary to amend a final sunscreen order under section 10.30, title 21 Code of Federal Regulations (or any successor regulations). If the Secretary grants any petition under such section, the Secretary shall initiate the process for amending a final sunscreen order by issuing a new proposed sunscreen order under subsection (a)(1) and following the procedures set forth in this section.
(C) *Applicability of final orders* — Once the Secretary issues a new proposed sunscreen order to amend a final sunscreen order under subparagraph (A) or (B), such final sunscreen order shall remain in effect and paragraph (3) shall not apply to such final sunscreen order until the Secretary has issued a new final sunscreen order or has determined not to amend the final sunscreen order.
(3) **Relationship to orders under [section 355h of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section355h&num=0&edition=prelim)** — A final sunscreen order shall be deemed to be a final order under [section 355h of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section355h&num=0&edition=prelim).
**(f) Exclusivity**
(1) **In general** — A final sunscreen order shall have the effect of authorizing solely the order requestor (or the licensees, assignees, or successors in interest of such requestor with respect to the subject of such request and listed under paragraph (5)) for a period of 18 months, to market a sunscreen ingredient under this section incorporating changes described in paragraph (2) subject to the limitations under paragraph (4), beginning on the date the requestor (or any licensees, assignees, or successors in interest of such requestor with respect to the subject of such request and listed under paragraph (5)) may lawfully market such sunscreen ingredient pursuant to the order.
(2) **Changes described** — A change described in this paragraph is a change subject to an order specified in paragraph (1) that permits a sunscreen to contain an active sunscreen ingredient not previously incorporated in a marketed sunscreen listed in paragraph (3).
(3) **Marketed sunscreen** — The marketed sunscreen ingredients described in this paragraph are sunscreen ingredients—
(A) marketed in accordance with a final monograph for sunscreen drug products set forth at part 352 of title 21, Code of Federal Regulations (as published at 64 Fed. Reg. 27687); or
(B) marketed in accordance with a final order issued under this section.
(4) **Limitations on exclusivity** — Only one 18-month period may be granted per ingredient under paragraph (1).
(5) **Listing of licensees, assignees, or successors in interest** — Requestors shall submit to the Secretary at the time when a drug subject to such request is introduced or delivered for introduction into interstate commerce, a list of licensees, assignees, or successors in interest under paragraph (1).
Cross-references
Connections may be documented source relationships, shared citations or nearby passages. Each explains its basis; a connection alone does not establish applicability to your situation.
Federal law — U.S. Code and appendices · legal_authorities
**(a) Nonprescription drugs marketed without an approved application** Nonprescription drugs marketed without an approved drug application under [section 355 of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section355&num=0&edition=prelim), as of March 27, 2020, shall be treated in accordance with this subsection.
(1) **Drugs subject to a final monograph; category I drugs subject to a tentative final monograph** — A drug is deemed to be generally recognized as safe and effective under [section 321(p)(1) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section321/p/1&num=0&edition=prelim), not a new drug under [section 321(p) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section321/p&num=0&edition=prelim), and not subject to [section 353(b)(1) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section353/b/1&num=0&edition=prelim), if—
(A) the drug is—
(i) in conformity with the requirements for nonprescription use of a final monograph issued under part 330 of title 21, Code of Federal Regulations (except as provided in paragraph (2)), the general requirements for nonprescription drugs, and conditions or requirements under subsections (b), (c), and (k); and
(ii) except as permitted by an order issued under subsection (b) or, in the case of a minor change in the drug, in conformity with an order issued under subsection (c), in a dosage form that, immediately prior to March 27, 2020, has been used to a material extent and for a material time under [section 321(p)(2) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section321/p/2&num=0&edition=prelim); or
(B) the drug is—
(i) clas
Source: Supplied U.S. Code snapshot — release unconfirmed · 21 U.S.C. § 355h
Stored review status: release_metadata_unconfirmed. Explicit cross-reference supplied in source Markdown; currentness and applicability require review.
Federal law — U.S. Code and appendices · legal_authorities
**(a) Necessity of effective approval of application** No person shall introduce or deliver for introduction into interstate commerce any new drug, unless an approval of an application filed pursuant to subsection (b) or (j) is effective with respect to such drug.
**(b) Filing application; contents**
(1)
(A) Any person may file with the Secretary an application with respect to any drug subject to the provisions of subsection (a). Such persons shall submit to the Secretary as part of the application—
(i) full reports of investigations which have been made to show whether such drug is safe for use and whether such drug is effective in use;
(ii) a full list of the articles used as components of such drug;
(iii) a full statement of the composition of such drug;
(iv) a full description of the methods used in, and the facilities and controls used for, the manufacture, processing, and packing of such drug;
(v) such samples of such drug and of the articles used as components thereof as the Secretary may require;
(vi) specimens of the labeling proposed to be used for such drug;
(vii) any assessments required under [section 355c of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section355c&num=0&edition=prelim); and
(viii) the patent number and expiration date of each patent for which a claim of patent infringement could reasonably be asserted if a person not licensed by the owner of the patent engaged in the manufacture, use, or sale of the drug, and that—
(I) claims the drug for which the applicant submitted the application and is a drug substance (active ingredient) patent or a drug product (formulation or composition) patent; or
(II) claims a method of using such drug for which approv
Source: Supplied U.S. Code snapshot — release unconfirmed · 21 U.S.C. § 355
Stored review status: release_metadata_unconfirmed. Explicit cross-reference supplied in source Markdown; currentness and applicability require review.
Federal law — U.S. Code and appendices · legal_authorities
In this part—
(1) the term “Advisory Committee” means the Nonprescription Drug Advisory Committee of the Food and Drug Administration or any successor to such Committee;
(2) the term “final sunscreen order” means an order published by the Secretary in the Federal Register containing information stating that a nonprescription sunscreen active ingredient or combination of nonprescription sunscreen active ingredients—
(A) is GRASE and is not misbranded if marketed in accordance with such order; or
(B) is not GRASE and is misbranded;
(3) the term “GRASE” means generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling of a drug as described in [section 321(p) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section321/p&num=0&edition=prelim);
(4) the term “GRASE determination” means, with respect to a nonprescription active ingredient or a combination of nonprescription active ingredients, a determination of whether such ingredient or combination of ingredients is GRASE;
(5) the term “nonprescription” means not subject to [section 353(b)(1) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section353/b/1&num=0&edition=prelim);
(6) the term “pending request” means each request with respect to a nonprescription sunscreen active ingredient submitted under section 330.14 of title 21, Code of Federal Regulations (as in effect on November 26, 2014) for consideration for inclusion in the over-the-counter drug monograph system—
(A) that was determined to be eligible for such review by publication of a notice of eligibilit
Source: Supplied U.S. Code snapshot — release unconfirmed · 21 U.S.C. § 360fff
Stored review status: release_metadata_unconfirmed. Explicit cross-reference supplied in source Markdown; currentness and applicability require review.
Federal law — U.S. Code and appendices · legal_authorities
Whoever, being an officer or employee of the United States or of any department or agency thereof, any person acting on behalf of the Federal Housing Finance Agency, or agent of the Department of Justice as defined in the Antitrust Civil Process Act ([15 U.S.C. 1311–131](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title15-section1311–131&num=0&edition=prelim)4), or being an employee of a private sector organization who is or was assigned to an agency under chapter 37 of title 5, publishes, divulges, discloses, or makes known in any manner or to any extent not authorized by law any information coming to him in the course of his employment or official duties or by reason of any examination or investigation made by, or return, report or record made to or filed with, such department or agency or officer or employee thereof, which information concerns or relates to the trade secrets, processes, operations, style of work, or apparatus, or to the identity, confidential statistical data, amount or source of any income, profits, losses, or expenditures of any person, firm, partnership, corporation, or association; or permits any income return or copy thereof or any book containing any abstract or particulars thereof to be seen or examined by any person except as provided by law; shall be fined under this title, or imprisoned not more than one year, or both; and shall be removed from office or employment.
Source: Supplied U.S. Code snapshot — release unconfirmed · 18 U.S.C. § 1905
Stored review status: release_metadata_unconfirmed. Explicit cross-reference supplied in source Markdown; currentness and applicability require review.